News
Two former Commerce Department executives take on intellectual property protection
Former Commerce, USPTO Heads Push for U.S. to Lead Opposition to Extending WTO’s COVID IP Waiver
Is China set to pass the US as the world’s lead innovators?
Iancu-Backed Group Urges Lawmakers To Support Tillis IP Bill
Letters Seek to Dispel Gene Patent ‘Scaremongering’ Surrounding Tillis’ Patent Eligibility Bill
“Any suggestion that this legislation would allow companies to patent anyone’s DNA is simply false,” C4IP writes, adding that the ‘scaremongering’…ignores the fact that the human genome has already been published many times over and is already available for scientific use.”
Patents for Human Genes, Diagnostic Tests Generate Policy Debate
Isolated human genes would be patentable, and the costs of medical diagnostic tests would jump under a recently introduced bill to revamp patent eligibility, panelists at an American Civil Liberties Union virtual briefing said Monday—a stance that former patent officials labeled “scaremongering.”
New high-level lobby group will promote role of IP in US innovation
Medicare has a herculean task ahead of setting up an infrastructure to take on an entirely new function for the program — regulating how much it pays for certain medications, and penalizing drug makers that hike prices faster than inflation. With new responsibility comes new bureaucracy, new documents obtained by STAT show.
Senator Coons’ co-sponsorship of Tillis bill potential breakthrough for patent eligibility
Medicare has a herculean task ahead of setting up an infrastructure to take on an entirely new function for the program — regulating how much it pays for certain medications, and penalizing drug makers that hike prices faster than inflation. With new responsibility comes new bureaucracy, new documents obtained by STAT show.
Bipartisan Group Aims To Halt ‘Downward’ Slide Of IP System
Medicare has a herculean task ahead of setting up an infrastructure to take on an entirely new function for the program — regulating how much it pays for certain medications, and penalizing drug makers that hike prices faster than inflation. With new responsibility comes new bureaucracy, new documents obtained by STAT show.